Citromycetin is a polyketide-derived fungal metabolite produced by Penicillium citrinum. It exhibits a broad spectrum of biological activities, including antibacterial, antifungal, and anti-inflammatory effects. The compound has been shown to inhibit the growth of various bacteria, including Staphylococcus aureus and Escherichia coli, as well as fungal pathogens like Candida albicans. Research into citromycetin is driven by its potential therapeutic applications. Its unique structural features and biological activities make it a promising lead compound for developing new antibiotics and anti-inflammatory agents. However, the clinical use of citromycetin is limited due to its potential toxicity. Ongoing research focuses on understanding its mechanism of action and exploring strategies to enhance its efficacy and safety.'
citromycetin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 65029 |
| SCHEMBL ID | 2137852 |
| MeSH ID | M0061221 |
| Synonym |
|---|
| NSC53584 , |
| 478-60-4 |
| nsc-53584 |
| citromycetin |
| 4h,2-c][1]benzopyran-10-carboxylic acid, 8,9-dihydroxy-2-methyl-4-oxo- |
| DIVK1C_006451 |
| KBIO1_001395 |
| SPECTRUM_000290 |
| ACON1_002335 |
| nsc 53584 |
| brn 0330020 |
| 4h,5h-pyrano(3,2-c)(1)benzopyran-10-carboxylic acid, 8,9-dihydroxy-2-methyl-4-oxo- |
| 8,9-dihydroxy-2-methyl-4-oxo-4h,5h-pyrano[3,2-c]chromene-10-carboxylic acid |
| 8,9-dihydroxy-2-methyl-4-oxo-5h-pyrano[3,2-c]chromene-10-carboxylic acid |
| frequentic acid |
| SPECTRUM5_000777 |
| KBIO2_000770 |
| KBIOSS_000770 |
| KBIO2_005906 |
| KBIO2_003338 |
| SPECPLUS_000355 |
| NCGC00169943-01 |
| unii-6lq9jp1ya7 |
| 4-19-00-03953 (beilstein handbook reference) |
| 6lq9jp1ya7 , |
| SCHEMBL2137852 |
| 4h,5h-pyrano[3,2-c][1]benzopyran-10-carboxylicacid, 8,9-dihydroxy-2-methyl-4-oxo- |
| citromycetin [mi] |
| 8,9-dihydroxy-2-methyl-4-oxo-4h,5h-pyrano(3,2-c)(1)benzopyran-10-carboxylic acid |
| DTXSID60197283 |
| 8,9-dihydroxy-2-methyl-4-oxo-4h,5h-pyrano[3,2-c][1]benzopyran-10-carboxylic acid |
| Q15410873 |
| CS-0065609 |
| HY-116479 |
| AKOS040748138 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.85) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||